Fulcrum Therapeutics, Inc.
NASDAQ: FULC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander C. Sapir
- Employees
- 45
- Headquarters
- Cambridge, United States
- IPO year
- 2019
- Market cap
- $203.5M
- Website
- https://www.fulcrumtx.com
Loading FULC…
Loading profile data…Frequently asked questions about FULC
What does Fulcrum Therapeutics, Inc. (FULC) do?
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular...
Where does FULC trade?
Fulcrum Therapeutics, Inc. (FULC) trades on the NASDAQ Global Market.
What sector is FULC in?
Fulcrum Therapeutics, Inc. (FULC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Fulcrum Therapeutics, Inc.?
Alexander C. Sapir is the chief executive officer of Fulcrum Therapeutics, Inc. (FULC).
Where is Fulcrum Therapeutics, Inc. headquartered?
Fulcrum Therapeutics, Inc. is headquartered in United States.
Does FULC pay a dividend?
Fulcrum Therapeutics, Inc. (FULC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FULC go public?
Fulcrum Therapeutics, Inc. (FULC) completed its initial public offering in 2019.